Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28750768 | 0.78 | DGAT1 (0.36) | DGAT1HPGDMAPTCTSKUSP2 | |
| SCHEMBL4948386 | 0.78 | DGAT1 (0.41) | DGAT1HPGDCTSKUSP2SMN1; SMN2 | |
| SCHEMBL2433463 | 0.78 | DGAT1 (0.36) | DGAT1HPGDMAPTCTSKUSP2 | |
| SCHEMBL2431943 | 0.78 | DGAT1 (0.33) | DGAT1MAPT | |
| SCHEMBL2433990 | 0.73 | DGAT1 (0.35) | DGAT1HPGDCTSKUSP2SMN1; SMN2 | |
| SCHEMBL18921418 | 0.72 | CTSK (0.42) | DGAT1HPGDMAPTCTSKUSP2 | |
| SCHEMBL3163754 | 0.69 | HPGD (0.38) | DGAT1HPGDCTSKUSP2SMN1; SMN2 | |
| SCHEMBL8563199 | 0.68 | CTSK (0.36) | DGAT1HPGDCTSKUSP2SMN1; SMN2 | |
| SCHEMBL10760132 | 0.68 | DGAT1 (0.34) | DGAT1HPGDCTSKUSP2SMN1; SMN2 | |
| SCHEMBL14213166 | 0.64 | DGAT1 (0.50) | DGAT1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | DGAT1 1447/4885HPGD 1752/4885MAPT 4775/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | DGAT1 1251/4885HPGD 1734/4885MAPT 4773/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | DGAT1 1581/4885HPGD 2201/4885MAPT 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.